% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pabst:302995,
      author       = {K. M. Pabst$^*$ and W. P. Fendler$^*$ and L. S.
                      Jochheim$^*$ and K. Herrmann$^*$},
      title        = {{T}he {V}alue of {FAPI} {PET}/{CT} in {C}holangiocarcinoma
                      and {P}ancreatic {C}ancer: {A}n {U}pdate.},
      journal      = {Seminars in nuclear medicine},
      volume       = {55},
      number       = {5},
      issn         = {0001-2998},
      address      = {New York, NY [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01442},
      pages        = {701-709},
      year         = {2025},
      note         = {Volume 55, Issue 5, September 2025, Pages 701-709},
      abstract     = {To date, contrast-enhanced CT (ceCT), magnetic resonance
                      imaging (MRI), and, in selected cases,
                      18F-fluorodeoxyglucose positron emission tomography/computed
                      tomography (18F-FDG PET/CT) are the current standard imaging
                      modalities for staging of pancreatic cancer and
                      cholangiocarcinoma. Fibroblast activation protein alpha
                      (FAP) has gained interest as a promising molecular imaging
                      target, particularly in tumors with a pronounced
                      desmoplastic reaction such as pancreatic cancer and
                      cholangiocarcinoma. Radiolabeled FAP inhibitors (FAPIs)
                      enable noninvasive visualization of cancer using PET/CT.
                      Recent studies have demonstrated that FAPI PET/CT provides
                      superior sensitivity compared to ceCT and 18F-FDG PET/CT in
                      cholangiocarcinoma and pancreatic cancer for detecting
                      primary tumors, lymph node involvement, and distant
                      metastases, particularly in hepatic metastases due to low
                      physiological background uptake. Furthermore, FAPI PET/CT
                      has been shown to affect TNM staging and subsequently alter
                      treatment-decision making. Beyond staging, early evidence
                      suggests a prognostic potential of FAPI PET/CT in tumor
                      grading, therapy response assessment, and survival outcomes,
                      although data remain limited. On the other hand, FAPI PET/CT
                      comes with limitations, particularly in the context of
                      fibrotic and inflammatory processes such as liver cirrhosis,
                      pancreatitis, or primary sclerosing cholangitis, which may
                      result in false-positive findings. This review summarizes
                      the current clinical evidence for FAPI PET/CT in pancreatic
                      cancer and cholangiocarcinoma, with a focus on diagnostic
                      performance, prognostic relevance, therapeutic implications,
                      and potential pitfalls.},
      subtyp        = {Review Article},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40675899},
      doi          = {10.1053/j.semnuclmed.2025.06.011},
      url          = {https://inrepo02.dkfz.de/record/302995},
}